Trial Profile
Safety and efficacy of cabozantinib in patients with metastatic renal cell carcinoma: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2017
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 20 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium